---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-006206"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2022-04-28T23:59:59+00:00"
generated_at: "2026-06-26T03:11:47.603705+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics Q1 cash $76.5M; Phase 3 uproleselan OS events trigger now mid-2023; workforce cut 20%

## Summary
- Cash and cash equivalents $76.5M at March 31, 2022, down from $90.3M at Dec 31, 2021.
- Phase 3 uproleselan trial in relapsed/refractory AML expects OS events trigger mid-2023, top line data shortly after.
- IND-enabling studies for GMI-1687 completed; submission on track for H1 2022 in sickle cell disease VOC.
- Workforce reduced by 20% in April, mainly early-stage research; executive team added CCO and VP of Tech Ops.
- R&D expenses $9.6M (down from $11.1M); G&A $5.1M (up from $4.2M); no revenue recognized.

## SEC filing metadata
- accession: 0001558370-22-006206
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2022-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837022006206/0001558370-22-006206-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837022006206/glyc-20220428x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-006206
- JSON: https://secwatch.observer/filing/0001558370-22-006206.json
- Plain text: https://secwatch.observer/filing/0001558370-22-006206.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.